FUNDAMENTALS · Fundamentals · TW Healthcare

Great Tree Pharmacy (6469) Fundamentals 2026 — P/E 20.6x, Revenue Analysis | SniperIQ

Great Tree Pharmacy (6469) is a TW-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of NT

1.7B, trading at NT$78.10 on the TWO. This SniperIQ fundamentals page covers Great Tree Pharmacy's valuation (P/E 20.6x, P/B 3.2x), profitability (net margin 3.0%), revenue (NT
8.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
1.7B
P/E (TTM)20.6x
Net Margin3.0%
Revenue (FY25)NT
8.9B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Great Tree Pharmacy's market cap?

Great Tree Pharmacy (6469) has a market capitalization of approximately NT

1.7B, trading at NT$78.10 on the TWO. Market cap moves with the live share price.

What is Great Tree Pharmacy's P/E ratio?

Great Tree Pharmacy's trailing twelve-month P/E ratio is 20.6x, with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Great Tree Pharmacy?

Great Tree Pharmacy runs a net profit margin of 3.0%, a gross margin of 28.7%, and an operating margin of 3.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Great Tree Pharmacy generate?

Great Tree Pharmacy reported revenue of NT

8.9B for fiscal year 2025, with net income of NT$600M and earnings per share (EPS) of 4.01. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Great Tree Pharmacy pay a dividend?

Great Tree Pharmacy offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Great Tree Pharmacy financially healthy?

Great Tree Pharmacy carries a debt-to-equity ratio of 1.93x and a current ratio of 1.48x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Great Tree Pharmacy a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Great Tree Pharmacy (6469) the key facts are: market cap NT

1.7B, P/E 20.6x, revenue NT
8.9B, 52-week range 68.8-147.3626. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Great Tree Pharmacy's full fundamentals live

Get Great Tree Pharmacy's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Universal Vision Biotechnology (3218) fundamentals · Vizionfocus (4771) fundamentals · Zhejiang Medicine (600216) fundamentals · Summit Therapeutics (SMMT) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons